

Literatura ACTA MEDICINAE 5–7/2023 Gynekologie | Onkogynekologie | Urologie

- 2 **Tibolon – 35 let bezpečné a účinné léčby estrogenního deficitu v klinické praxi**
doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 2. LF UK a FN v Motole, Katedra zdravotnických studií, Vysoká škola polytechnická Jihlava
- 2 **Systémová léčba recidivujícího karcinomu endometria a děložního hrdla – nové možnosti**
prof. MUDr. Michal Zikán, Ph.D. Gynekologicko-porodnická klinika FN Bulovka a 1. LF UK, Praha
- 3 **Črevný mikrobióm a endometrióza**
MUDr. Terézia Pribulová Gynekologicko-pôrodnická klinika, Jesseniova lekárska fakulta Martin, Univerzita Komenského Bratislava
MUDr. Katarína Fiolková | MUDr. Roman Fiolka, PhD. Gynfull, s. r. o., Žilina
MUDr. Michaela Hrtánková, PhD. | MUDr. Jana Siváková, PhD. | doc. MUDr. Kamil Biringer, PhD. Gynekologicko-pôrodnická klinika, Jesseniova lekárska fakulta Martin, Univerzita Komenského Bratislava
- 3 **Infekce v gynekologii: bakteriální vaginóza**
doc. MUDr. Petr Hamal, Ph.D., FECMM | MDDr. Lucie Svobodová, Ph.D. Ústav mikrobiologie Lékařské fakulty UP a Fakultní nemocnice Olomouc
- 3 **HPV infekce a její prevence**
MUDr. Lucie Mouková, Ph.D. Klinika operační onkologie, Oddělení gynekologické onkologie, Ambulance cervikální patologie MOÚ, Brno
- 3 **Prenatální infekce a jejich důsledky**
MUDr. Markéta Geleneky Klinika infekčních nemocí 3. LF UK a Fakultní nemocnice Bulovka, Praha
- 4 **Suplementace železem u žen ve fertilním věku**
doc. PharmDr. Miloslav Hronek, Ph.D. | PharmDr. Miroslav Kovařík, Ph.D. Farmaceutická fakulta v Hradci Králové, Univerzita Karlova
- 4 **Anemie a léčba železem v graviditě**
MUDr. Dagmar Seidlová, Ph.D. II. Anesteziologicko-resuscitační oddělení a Klinika anesteziologie, resuscitace a intenzivní medicíny, Fakultní nemocnice Brno, LF MU, Brno
MUDr. Romana Gerychová Gynekologicko-porodnická klinika, Fakultní nemocnice Brno, LF MU, Brno
- 4 **Aktuální možnosti léčby inkontinence moči u žen**
MUDr. Petr Hubka, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha
- 5 **Význam antimüllerického hormonu pro klinickou praxi**
MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, 3. LF UK, IPVZ, Praha
- 5 **Antikoagulační léčba žilních tromboembolických příhod**
MUDr. Karolína Kočí Interní klinika 1. LF UK a ÚVN, Praha
- 5 **Obinutuzumab a bendamustin dosáhly u pěti pacientů s Waldenströmovou makroglobulinémií hlubší léčebné odpovědi než předchozí linie léčby**
prof. MUDr. Zdeněk Adam, CSc. | prof. MUDr. Luděk Pour, Ph.D. Interní hematologická a onkologická klinika LF MU a FN Brno
MUDr. Ing. David Zeman, Ph.D. Ústav laboratorní medicíny – Oddělení klinické biochemie, LF MU a FN Brno
doc. MUDr. Marta Krejčí, Ph.D. | MUDr. Viera Sandecká, Ph.D. Interní hematologická a onkologická klinika LF MU a FN Brno

Tibolon – 35 let bezpečné a účinné léčby estrogenního deficitu v klinické praxi

doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 2. LF UK a FN v Motole, Katedra zdravotnických studií,

Vysoká škola polytechnická Jihlava

- Landgren, M. B. – Coelingh Bennink, H. J. T. – Helmond, F. A., et al.: Dose response analysis of effect of tibolone on climacteric symptoms. *Br J Obstet Gynaecol*, 2002, 109, s. 1109–1114.
- Hammar, M. – Christau, S. – Nathorst-Boos, J., et al.: A double blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal symptoms. *Br J Obstet Gynaecol*, 1998, 105, s. 904–911.
- Huber, J. – Palacios, S. – Berglund, L., et al.: The effect of tibolone compared with CEE continuously combined with medroxyprogesterone acetate on bleeding rates, quality of life and tolerability in postmenopausal women. *Br J Obstet Gynaecol*, 2002, 109, s. 886–893.
- Mendoza, N. – Pison, J. A. – Fernandez, M., et al.: Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus. *Maturitas*, 2002, 41, s. 289–298.
- Baracat, E. C. – Barbosa, I. C. – Giordano, M. G., et al.: A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. *Climacteric*, 2002, 5, s. 60–69.
- Davis, S. R.: The effect of tibolone on mood and libido. *Menopause*, 2002, 9, s. 162–170.
- Tax, L. – Goorissen, E. M. – Kucovic, P. M.: Clinical profile Org OD14. *Maturitas*, 1987, suppl. 1, s. 3–13.
- Lindsay, P. C. – Shaw, R. W. – Coeling Benning, H. J., et al.: The effect of add back treatment with tibolone on patients treated with the GnRH agonist triptorelin. *Fertil Steril*, 1996, 65, s. 342–348.
- Palomba, S. – Affinito, P. – Di Carlo, C., et al.: Long-term administration of tibolone plus GnRH agonist for the treatment of uterine leiomyomas. *Fertil Steril*, 1999, 72, s. 889–895.
- Egarter, C. – Sator, M. – Berghammer, P., et al.: Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women. *Int J Gynecol Obstet*, 1999, 64, s. 281–286.
- Kenemans, P. – Speroff, L.: Tibolone: clinical recommendations and practical guidelines. *Maturitas*, 2005, 51, s. 21–28.
- Meeuwssen, I. B. – Samson, M. M. – Duursma, S. A., et al.: The influence of tibolone on quality of life in postmenopausal women. *Maturitas*, 2002, 41, s. 35–43.
- Fait, T. – Žižka, Z.: Mammographic density – a risk factor for breast cancer. *Prague Medical Report*, 2007, 108, s. 205–214.
- Valdivia, I. – Campodónico, I. – Capia, A., et al.: Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. *Fertil Steril*, 2004, 81, s. 617–623.
- Lundström, E. – Christow, A. – Kersemaekers, W., et al.: Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. *AJOG*, 2002, 186, s. 717–722.
- Bruce, D. – Robinson, J. – McWilliams, S., et al.: Long term effects of tibolone on mammographic density. *Fertil Steril*, 2004, 82, s. 1343–1347.
- Yenen, M. C. – Dede, M. – Goktolga, U., et al.: Hormone replacement therapy in postmenopausal women with benign fibrocystic mastopathy. *Climacteric*, 2003, 6, s. 146–150.
- Hammar, M. – Christau, S. – Nathorst-Boos, J., et al.: A double blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. *BJOG*, 1998, 105, s. 904–911.
- Huber, J. – Palacios, S. – Berglund, L., et al.: Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. *BJOG*, 2002, 109, s. 886–893.
- Speroff, L.: The Million Women Study and breast cancer. *Maturitas*, 2003, 46, s. 1–6.
- Rymer, J. – Robinson, J. – Fogelman, I.: 10 years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. *Climacteric*, 2002, 5, s. 390–398.
- Roux, C. – Pelissier, C. – Fechtenbaum, J., et al.: Randomized, double-blind, 2-year comparison of tibolone with 17β-estradiol and norethindrone acetate in preventing postmenopausal bone loss. *Osteoporosis Int*, 2002, 13, s. 241–248.
- Gallagher, J. C. – Baylink, D. J. – Freeman, R., et al.: Prevention of bone loss with tibolone in postmenopausal women; results of two-randomised, double-blind, placebo-controlled, dose finding studies. *J Clin Endocrinol Metab*, 2001, 86, s. 4717–4726.
- Berning, B. – Kujik, C. V. – Kuiper, P. M., et al.: Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. *Bone*, 1996, 19, s. 395–399.
- Bjarnason, N. H. – Bjarnason, K. – Haarbo, J., et al.: Tibolone: prevention of bone loss in late postmenopausal women. *J Clin Endocrinol Metab*, 1996, 81, s. 2419–2422.
- Studd, J. – Arnala, I. – Kicovic, P. M., et al.: Tibolone increases bone mineral density in osteoporotic post-menopausal women in a randomized study. *Obstet Gynecol*, 1998, 92, s. 574–579.
- Lippuner, K. – Haenggi, W. – Birkhäuser, M. H., et al.: Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17β-estradiol and dydrogesterone. *J Bone Miner Res*, 1997, 12, s. 806–812.
- Prelevic, G. M. – Bartram, C. – Wood, J., et al.: Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progesterone therapy in postmenopausal women. *Gynecol Endocrinol*, 1996, 10, s. 413–420.
- Nijland, E. A. – Nathorst-Boos, J. – Palacios, S., et al.: Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. *Climacteric*, 2009, 12, s. 114–121.
- Nijland, E. A. – Weijmar Schultz, W. C. – Nathorst-Boos, J., et al.: Tibolone and E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women. *J Sex Med*, 2008, 5, s. 646–656.
- Delmas, P. D. – Davis, S. R. – Hensen, J., et al.: Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. *Osteoporosis Int*, 2008, 19, s. 1153–1160.
- Cummings, S. R. – Ettinger, B. – Delmas, P. D., et al.: The effect of tibolone in older postmenopausal women. *N Engl J Med*, 2008, 359, s. 697–708.
- Kenemans, P. – Bundred, N. J. – Foidart, J. M., et al.: Safety and efficacy of tibolone in breast cancer patients with vasomotor symptoms: a double-blind randomised, non-inferiority trial. *Lancet Oncol*, 2009, 10, s. 135–146.
- Archer, D. F. – Hendrix, S. – Ferenczy, A., et al.: Tibolone histology of the endometrium and breast endpoints study. *Fertil Steril*, 2007, 88, s. 866–878.
- Archer, D. F. – Hendrix, S. – Gallagher, J. C., et al.: Endometrial effects of tibolone. *J Clin Endocrinol Metab*, 2007, 92, s. 911–918.
- Hammar, M. L. – van de Weijer, P. – Franke, H. R., et al.: Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. *BJOG*, 2007, 114, s. 1522–1529.
- Bots, M. L. – Evans, G. W. – Riley, W., et al.: The effect of tibolone and continuous combined CEE plus MPA on progression of CIM thickness. *Eur Heart J*, 2006, 27, s. 746–755.
- Langer, R. D. – Landgren, B. M. – Rymer, J., et al.: Effects of tibolone and continuous CEE/MPA on the endometrium and vaginal bleeding. *AJOG*, 2006, 195, s. 1320–1327.
- Fait, T.: Falešné obavy z hormonální substituční terapie škodí zdraví žen. *Gyn Por*, 2023, 7, s. 4–10.

Systemová léčba recidivujícího karcinomu endometria a děložního hrdla – nové možnosti

prof. MUDr. Michal Zikán, Ph.D. Gynekologicko-porodnická klinika FN Bulovka a 1. LF UK, Praha

- Kagabu, M. – Nagasawa, T. – Sato, C., et al.: Immunotherapy for uterine cervical cancer using checkpoint inhibitors: future directions. *Int J Mol Sci*, 2020, 21, s. 2335.
- Peralta-Zaragoza, O. – Bermúdez-Morales, V. H. – Pérez-Plasencia, C., et al.: Targeted treatments for cervical cancer: a review. *Oncol Targets Ther*, 2012, 5, s. 315–328.
- Jazaeri, A. A. – Zsiros, E. – Amaria, R. N., et al.: Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. *J Clin Oncol*, 2019, 37, suppl. 15, s. 2538.
- Eskander, R. N. – Tewari, K. S.: Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. *Clinical Therapeutics*, 2015, 37, s. 20–38.
- Enwere, E. K. – Kornaga, E. N. – Dean, M., et al.: Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. *Mod Pathol*, 2017, 30, s. 577–586.
- Browne, I. – Fennelly, D. W. – Crown, J., et al.: The efficacy and safety of pembrolizumab in advanced cervical cancer – A real World treatment study in an Irish healthcare setting. *J Clin Oncol*, 2020, 38, suppl. 15, DOI: 10.1200/JCO.2020.38.15_suppl.18007
- da Silva, D. M. – Enserro, D. M. – Mayadev, J. S., et al.: Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929). *Clinical Cancer Research*, 2021, 26, s. 5621–5630.
- Naumann, R. W. – Oaknin, A. – Meyer, T., et al.: Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: results from CheckMate 358. *Ann Oncol*, 2019, 30, suppl. 5, LBA62.
- Tewari, K. S. – Monk, B. J. – Vergote, I., et al.: VP4-2021: EMPower-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma. *Ann Oncol*, 2021, 32, s. 940–941.
- O'Malley, D. M. – Oaknin, A. – Monk, B. J., et al.: Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials. *Ann Oncol*, 2020, 31, suppl. 4, s. S1164–S1165.
- O'Malley, D. – Neffa, M. – Monk, B. J., et al.: 724MO Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC). *Ann Oncol*, 2021, 32, s. S727.
- Colombo, N. – Dubot, C. – Lorusso, D., et al.: LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study. *Ann Oncol*, 2021, 32, s. S1307–S1308.
- Song, Y. – Wang, C. – Li, X., et al.: 782P A retrospective study of toripalimab combined with concurrent chemoradiotherapy in patients with recurrent/advanced cervical cancer. *Ann Oncol*, 2021, 32, s. S755.
- Frenel, J. S. – Hervieu, A. – Borcoman, E., et al.: 775P Tremelimumab (T) + durvalumab (D) combined with metronomic oral vinorelbine (MOV): Results of the recurrent cervical cancer (RCC) cohort of the MOVIE study. *Ann Oncol*, 2021, 32, s. S753.
- Youn, J. W. – Hur, S. Y. – Woo, J. W., et al.: Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: Interim results of a single-arm, phase 2 trial. *Lancet Oncol*, 2020, 21, s. 1653–1660.
- Concin, N. – Matias-Guiu, X. – Vergote, I., et al.: ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. *Int J Gynecol Cancer*, 2021, 31, s. 12–39.
- Humber, C. E. – Tierney, J. F. – Symonds, R. P., et al.: Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. *Ann Oncol*, 2007, 18, s. 409–420.
- Fleming, G. F.: Second-line therapy for endometrial cancer: the need for better options. *J Clin Oncol*, 2015, 33, s. 3535–3540.
- Levine, D.: The Cancer Genome Atlas Research Network: Integrated genomic characterization of endometrial carcinoma. *Nature*, 2013, 497, s. 67–73.
- Marcus, L. – Lemery, S. J. – Keegan, P., et al.: FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. *Clin Cancer Res*, 2019, 25, s. 3753–3758.
- FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma. Dostupné z: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pembrolizumab-and-lenvatinib-advanced-endometrial-carcinoma>, vyhledáno 1. 12. 2021.
- Merck. European Commission Approves KEYTRUDA® (Pembrolizumab) Plus LENVIMA® (Lenvatinib) for Patients With Certain Types of Endometrial Carcinoma. Dostupné z: <https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-for-patients-with-certain-types-of-endometrial-carcinoma/>, vyhledáno 1. 12. 2021.
- ESMO. EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab. Dostupné z: <https://www.esmo.org/oncology-news/ema-recommends-granting-a-conditional-marketing-authorisation-for-dostarlimab>, vyhledáno 1. 12. 2021.
- Marabelle, A. – Le, D. T. – Ascierto, P. A., et al.: Efficacy of pembrolizumab in patients with non colorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 Study. *J Clin Oncol*, 2020, 38, s. 1–10.
- Le, D. T. – Durham, J. N. – Smith, K. N., et al.: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*, 2017, 357, s. 409–413.
- Fader, A. N. – Diaz, L. A. – Armstrong, D. K., et al.: Preliminary results of a phase II study: PD-1 blockade in mismatch repair-deficient, recurrent or persistent endometrial cancer. *Gynecol Oncol*, 2016, 141,

s. 206–207.

- 27 **Roque, D. M.** – Bellone, S. – Siegel, E. R., et al.: A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH1 methylated characteristics (NCT02899793). *JCO*, 2021, 39, s. 5523–5523.
- 28 **Ott, P. A.** – Bang, Y.-J. – Berton-Rigaud, D., et al.: Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 Study. *J Clin Oncol*, 2017, 35, s. 2535–2541.
- 29 **Makker, V.** – Taylor, M. H. – Aghajanian, C., et al.: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. *J Clin Oncol*, 2020, 38, s. 2981–2992.
- 30 **Makker, V.** – Colombo, N. – Casado Herráez, A., et al.: Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women's Cancer. A multicenter, open-label, randomized phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs. treatment of physician's choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775. *Int J Gynecol Cancer*, 2021, 31, s. A4–5.
- 31 **Tamura, K.** – Hasegawa, K. – Katsumata, N., et al.: Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. *Cancer Sci*, 2019, 110, s. 2894–2904.
- 32 **Lheureux, S.** – Matei, D. – Konstantinopoulos, P. A., et al.: A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. *JCO*, 2020, 38, suppl. 15,

s. 6010–6010.

- 33 **Oaknin, A.** – Duska, L. R. – Sullivan, R. J., et al.: Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H and MSS endometrial cancer. *Gynecologic Oncology*, 2019, 154, s. 17.
- 34 **Mirza, M. R.**, et al.: Dostarlimab for primary advanced or recurrent endometrial cancer. *N Engl J Med*, 2023, doi: 10.1056/NEJMoa2216334.
- 35 **Eskander, R. N.** – Sill, M. W. – Beffa, L., et al.: Pembrolizumab plus chemotherapy in advanced endometrial cancer. *N Engl J Med*, 2023, doi: 10.1056/NEJMoa2302312.

Črevný mikrobióm a endometrióza

MUDr. Terézia Pribulová Gynekologicko-pôrodnická klinika, Jesseniova lekárska fakulta Martin, Univerzita Komenského Bratislava

MUDr. Katarína Fiolková | MUDr. Roman Fiolka, PhD. Gynfull, s. r. o., Žilina

MUDr. Michaela Hrtánková, PhD. | MUDr. Jana Siváková, PhD. | doc. MUDr. Kamil Biringer, PhD. Gynekologicko-pôrodnická klinika, Jesseniova lekárska fakulta Martin, Univerzita Komenského Bratislava

- 1 **Shigeshi, N.**, et al.: The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis. *Hum Reprod Update*, 2019, 25, s. 486–503.
- 2 **Zondervan, K. T.** – Becker, C. M. – Missmer, S. A.: Endometriosis. *N Engl J Med*, 2020, 382, s. 1244–1256.
- 3 **Baker, J. M.** – Chase, D. M. – Herbst-Kralovetz, M. M.: Uterine microbiota: residents, tourists, or invaders?. *Front Immunol*, 2018, 9, s. 208.
- 4 **Chadchan, S. B.** – Singh, V. – Kommagani, R.: Female reproductive dysfunctions and the gut microbiota. *J Mol Endocrinol*, 2022, 69, s. R81–R94.
- 5 **Molina, N. M.** – Sola-Leyva, A. – Saez-Lara, M. J., et al.: New opportunities for endometrial health by modifying uterine microbial composition: present or future?. *Biomolecules*, 2020, 10, s. 593.
- 6 **Ogunrinola, G. A.**, et al.: The human microbiome and its impacts on health. *Int J Microbiol*, 2020, 8045646, doi.org/10.1155/2020/8045646.
- 7 **Reis, F. M.** – Petraglia, F. – Taylor, R. N.: Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. *Hum Reprod Update*, 2013, 19, s. 406–418.
- 8 **Li, Y.** – Wang, K. – Ding, J., et al.: Influence of the gut microbiota on endometriosis: Potential role of chenodeoxycholic acid and its derivatives. *Front Pharmacol*, 2022, 13, doi.org/10.3389/fphar.2022.954684.
- 9 **Moreno, I.**, et al.: Evidence that the endometrial microbiota has an effect on implantation success or failure. *Am J Obstet Gynecol*, 2016, 215, s. 684–703.
- 10 **Reis, F. M.** – Petraglia, F. – Taylor, R. N.: Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. *Hum Reprod Update*, 2013, 19, s. 406–418.
- 11 **Ata, B.**, et al.: The endobiota study: comparison of vaginal, cervical and gut microbiota between women with stage 3/4 endometriosis and healthy controls. *Sci Rep*, 2019, 9, s. 2204.
- 12 **Hernandes, C.**, et al.: Profile of deep endometriosis patients: comparison of vaginal fluid, endometrium and lesion. *Diagnostics*, 2020,

10, s. 163.

- 13 **Yuan, M.**, et al.: Endometriosis induces gut microbiota alterations in mice. *Hum Reprod*, 2018, 33, s. 607–616.
- 14 **Chadchan, S. B.**, et al.: Antibiotic therapy with metronidazole reduces endometriosis disease progression in mice: a potential role for gut microbiota. *Hum Reprod*, 2019, 34, s. 1106–1116.
- 15 **Bailey, M. T.** – Coe, C. L.: Endometriosis is associated with an altered profile of intestinal microflora in female rhesus monkeys. *Hum Reprod*, 2002, 17, s. 1704–1708.
- 16 **Qin, R.**, et al.: The gut microbiota and endometriosis: From pathogenesis to diagnosis and treatment. *Front Cell Infect Microbiol*, doi.org/10.3389/fcimb.2022.1069557.
- 17 **Chadchan, S. B.**, et al.: Gut microbiota-derived short-chain fatty acids protect against the progression of endometriosis. *Life Sci Alliance*, 2021, 4, s. e202101224.

Infekce v gynekologii: bakteriální vaginóza

doc. MUDr. Petr Hamal, Ph.D., FECMM | MDDr. Lucie Svobodová, Ph.D. Ústav mikrobiologie Lékařské fakulty UP a Fakultní nemocnice Olomouc

- 1 **Vieira-Baptista, P.** – Stockdale, C. K. – Sobel, J. (eds.): *International Society for the Study of Vulvovaginal Disease recommendations for the diagnosis and treatment of vaginitis*. Lisbon, Admedic, 2023, DOI: <https://doi.org/10.59153/adm.rdtv.001>.
- 2 **Paladine, H. L.** – Desai, U. A.: Vaginitis: diagnosis and treatment. *Am Fam Physician*, 2018, 97, s. 321–329.
- 3 **Chacra, L. A.** – Fenollar, F. – Diop, K.: Bacterial vaginosis: What do we currently know? *Front Cell Infect Microbiol*, 2022, 11, 672429, doi:

10.3389/fcimb.2021.672429.

Další literatura u autora

HPV infekce a její prevence

MUDr. Lucie Mouková, Ph.D. Klinika operační onkologie, Oddělení gynekologické onkologie, Ambulance cervikální patologie MOÚ, Brno

- 1 **Rosalik, K.** – Tarney, Ch. – Han, J.: Human papilloma virus vaccination. *Viruses*, 2021, 13, s. 1091.
- 2 **Shapiro, G. K.**: HPV vaccination: an under used strategy for the prevention of cancer. *Curr Oncol*, 2022, 29, s. 3780–3792.
- 3 **Kechagias, K. S.** – Kalliala, I. – Bowden, S. J., et al.: Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis. *BMI*, 2022, 378, s. e070135.
- 4 **Lechner, M.** – Liu, J. – Masterson, L., et al.: HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. *Nat Rev Clin Oncol*, 2022, 19, s. 306–327.
- 5 Screening karcinomu děložního hrdla od roku 2021. Dostupné z: <https://www.vzp.cz/o-nas/aktuality/screening-karcinomu-delozniho-hrdla-od-roku-2021>, vyhledáno 30. 3. 2023.
- 6 **Donato, V. D.** – Caruso, G. – Petrillo, M., et al.: Adjuvant HPV vaccination to prevent recurrent cervical dysplasia after surgical treatment: a meta-analysis. *Vaccines*, 2021, 9, s. 410.
- 7 www.hpv-guide.cz
- 8 www.cervix.cz
- 9 www.linkos.cz
- 10 **Okunade, K. S.**: Human papillomavirus and cervical cancer. *J Obstet Gynecol*, 2020, 40, s. 602–608.
- 11 **Hu, Z.** – Ma, D.: The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. *Cancer Medicine*, 2018, 7, s. 5217–5236.
- 12 **Ntanasis-Statopoulos, I.** – Kyriazoglou, A. – Liontos, M., et al.: Current trends in the management and prevention of human papillomavirus (HPV) infection. *J BUON*, 2020, 25, s. 1281–1285.
- 13 **Mouková, L.** – Ferenec, R.: Lidský papillomavirus z pohledu onkologie. *Onkologie*, 2010, 4, s. 243–246.
- 14 **Mouková, L.** – Ferenec, R. – Chovanec, J.: Vakcinace proti lidskému papillomaviru v České republice. *Klin Onkol*, 2010, 23, s. 125–126.

Prenatální infekce a jejich důsledky

MUDr. Markéta Geleneky Klinika infekčních nemocí 3. LF UK a Fakultní nemocnice Bulovka, Praha

- 1 **Leung, K. K. Y.**, et al.: Congenital infections in Hong Kong: an overview of TORCH. *Hong Kong Med J*, 2020, 26, s. 127–138.
- 2 The Center for Food Security and Public Health. Toxoplasmosis; 2017. Dostupné z: <http://www.cfsph.iastate.edu/Factsheets/pdfs/toxoplasmosis.pdf>, vyhledáno 7. 3. 2022.
- 3 **Dietrich, M. L.** – Schieffelin, J. S.: Congenital cytomegalovirus infection. *Ochsner J*, 2019, 19, s. 123–130.
- 4 **Faure Bardon, V.** – Ville, Y.: Maternal infections: revisiting the need for screening in pregnancy. *BJOG*, 2021, 128, s. 304–315.
- 5 **Stegmann, B. J.** – Carey, J. C.: TORCH Infections. Toxoplasmosis, Other (syphilis, varicella-zoster, parvovirus B19), Rubella, Cytomegalovirus (CMV), and Herpes infections. *Curr Womens Health Rep*, 2002, 2, s. 253–258.
- 6 **Jaán, A.** – Rajnik, M.: TORCH Complex. StatPearls. Treasure Island (FL): StatPearls Publishing, 2022. Dostupné z: <https://www.ncbi.nlm.nih.gov/books/NBK560528/>, vyhledáno 7. 3. 2022
- 7 **Geleneky, M.**: Kongenitální toxoplazmóza jako součást neonatologické problematiky. *Čes Slov Neonat*, 2022, 28, s. 107–110.
- 8 **Remington, J. S.** – Klein, J. O. – Nizet, V., et al.: *Infectious diseases of the fetus and newborn infant*. 2011, s. 1231–1260. Dostupné z: doi.org/10.1016/C2009-0-50442-4, vyhledáno 7. 3. 2022.
- 9 **Pomares, Ch.** – Montoya, J. G.: Laboratory diagnosis of congenital toxoplasmosis. *J Clin Microbiol*, 2016, 54, s. 2448–2454.
- 10 **Peyron, F.**, et al.: Maternal and congenital toxoplasmosis: diagnosis and treatment recommendations of a French Multidisciplinary Working Group. *Pathogens*, 2019, 8, s. 24.
- 11 **Smišková, D.**: Zoonózy – nejčastější klinické projevy a diferenciální diagnostika. *Medicína pro praxi*, 2010, 7, s. 384–386.
- 12 **Geleneky, M.** – Prášil, P. – Kodym, P.: Doporučený postup pro diagnostiku a léčbu toxoplazmózy. *Neonatologické listy*, 2019, 25,

Suplementace železem u žen ve fertilním věku

doc. PharmDr. Miloslav Hronek, Ph.D. | PharmDr. Miroslav Kovařík, Ph.D. Farmaceutická fakulta v Hradci Králové, Univerzita Karlova

- Lopez, A. – Cacoub, P. – Macdougall, I. C., et al.: Iron deficiency anaemia. *Lancet*, 2016, 387, s. 907–916.
- Hronek, M.: *Výživa ženy v období těhotenství a kojení*. Praha, Maxdorf, 2004.
- Hronek, M. – Barešová, H.: *Strava těhotných a kojících žen*. Praha, For-sapi, 2012.
- Dostupné z:
- Referenční hodnoty pro příjem živin. Společnost pro výživu, z. s., Praha, 2019, s. 269. Dostupné z: [## Anemie a léčba železem v graviditě](https://www.vyzivaspol.cz/referencni-hodnoty-pro-prijem-zivin-dach-2019/, vyhledáno 11. 3. 2023.
Sackmann, A. D. – Formanowicz, P. – Formanowicz, I., et al.: An analysis of the Petri net based model of the human body iron homeostasis process. <i>Computational Biology and Chemistry</i>, 2007, 31, s. 1–10.
Lynch, S. – Pfeiffer, C. M. – Georgieff, M. K., et al.: Biomarkers of nutrition for development (BOND)-iron review. <i>J Nutr</i>, 2018, 148, suppl. 1, s. 1001S–1067S.
Novotný, J.: Sideropenická anemie. <i>Medicina pro praxi</i>, 2007, 4, s. 390–394.
Reddy, P. S. – Adsul, B. B. – Gandewar, K., et al.: Evaluation of efficacy of iron polymaltose complex and folic acid (Mumfer) vs iron formulation (ferrous fumarate) in female patients with anaemia. <i>J Indian Med Assoc</i>, 2001, 99, s. 154–155.
Cofnas, N.: Is vegetarianism healthy for children? <i>Crit Rev Food Sci Nutr</i>, 2019, 59, s. 2052–2060.
Geisser, P.: In vitro studies on interaction of iron salts and complexes with food-stuffs and medicaments. <i>Arzneimittelforschung</i>, 1990, 40, s. 754–760.
Zajícová, M.: Farmaceutická péče u pacientů se substitucí železa při anemii. <i>Prakt lékáren</i>, 2012, 8, s. 225–226.

</div>
<div data-bbox=)

MUDr. Dagmar Seidlová, Ph.D. II. Anesteziologicko-resuscitační oddělení a Klinika anesteziologie, resuscitace a intenzivní medicíny, Fakultní nemocnice Brno, LF MU, Brno

MUDr. Romana Gerychová Gynekologicko-porodnická klinika, Fakultní nemocnice Brno, LF MU, Brno

- Bulíková, A. – Kísová, J.: Anemie v praxi. *Interní Med*, 2011, 13, s. 31–34.
- ČGPS ČLS JEP Zásady dispenzární péče v těhotenství. Perinatologie.eu [online], 2021, 1.
- Harper, J. L. – Conrad, M. E.: Iron Deficiency Anemia. Dostupné z: [## Aktuální možnosti léčby inkontinence moči u žen](https://emedicine.medscape.com/article/202333-overview, vyhledáno 25. 5. 2023
Hronek, M. – Kovařík, M., et al.: Deficit příjmu železa – nutriční zdroj, doporučené denní dávky, suplementace železem. <i>Med Praxi</i>, 2022, 19, s. 119–122.
Lopez, A. – Cacoub, P. – Macdougall, I. C., et al.: Iron deficiency anaemia. <i>Lancet</i>, 2016, 387, s. 907–916.
Milman, N., et al.: Iron status in pregnant women and women of reproductive age in Europe. <i>Am J Clin Nutr</i>, 2017, 106, suppl. 6, s. 1655S–1662S.
Novotná, M. – Calda, P.: Železo v těhotenství. <i>Actual Gyn</i>, 2016, 8, s. 48–53.
Novotný, J., et al.: Sideropenická anemie. <i>Med Pro Praxi</i>, 2007, 4, s. 390–394.
Palátová, A., et al.: Sideropenická anemie malnutriční etiologie. <i>Česlov Pediatr</i>, 2021, 76, s. 262–266.
Peña-Rosas, J. P. – De-Regil, L. M. – Garcia-Casal, M. N., et al.: Daily oral iron supplementation during pregnancy. <i>Cochrane Database Syst Rev</i>, 2015, 2015, CD004736.
Pollit, E., et al.: Iron deficiency and behavioral development in infants and preschool children. <i>Am J Clin Nutr</i>, 1986, 43, s. 555–565.
Stourac, P., et al.: Changes in caesarean section anaesthesia between 2011 and 2015: Czech and Slovak national surveys. <i>Eur J Anaesthesiol</i>, 2019, 36, s. 801–803.
Wang, M.: Iron deficiency and other types of anemia in infants and children. <i>Am Fam Physician</i>, 2016, 93, s. 270–278.
Wang, F. – Liu, H. – Wan, Y., et al.: Prolonged exclusive breast feeding duration is positively associated with risk of anemia in infant saged 12 months. <i>J Nutr</i>, 2016, 146, s. 1707–1713.

</div>
<div data-bbox=)

MUDr. Petr Hubka, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha

- Haylen, B. T. – de Ridder, D. – Freeman, R. M., et al.: An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Int Urogynecol J*, 2010, 21, s. 5–26.
- Nambiar, A. K. – Arlandis, S. – Bø, K., et al.: European Association of Urology Guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: Diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. *Eur Urol*, 2022, 82, s. 49–59.
- Gágyor, D.: Současné možnosti ultrazvukové diagnostiky v gynekologii. *Ceska gynekol*, 2016, 4, s. 265–271.
- Hubka, P. – Masata, J. – Martan, A., et al.: Sonographic findings and effect of sling procedures for stress urinary incontinence. *Ultrasound Obstet Gynecol*, 2022, doi: 10.1002/uog.26142.
- Vytisková, T. – Masata, J. – Svabik, K., et al.: Classification of descent and mobility of urethrovesical junction in women with stress urinary incontinence – an ultrasound study. *Ceska Gynekol*, 2018, 83, s. 188–194.
- Svabik, K. – Hubka, P. – Masata, J., et al.: How accurate are we in urethral mobility assessment? Comparison of subjective and objective assessment. *Ceska Gynekol*, 2018, 83, s. 257–262.
- Kelleher, C. J. – Cardozo, L. D. – Khullar, V., et al.: A new questionnaire to assess the quality of life of urinary incontinent women. *Br J Obstet Gynaecol*, 1997, 104, s. 1374–1379.
- Rogers, R. G. – Coates, K. W. – Kammerer-Doak, D., et al.: A short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). *Int Urogynecol J Pelvic Floor Dysfunct*, 2003, 14, s. 164–168, diskuze s. 168.
- Uebersax, J. S. – Wyman, J. F. – Shumaker, S. A., et al.: Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. *NeuroUrol Urodyn*, 1995, 14, s. 131–139.
- Yamada, S. – Ito, Y. – Nishijima, S., et al.: Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. *Pharmacol Ther*, 2018, 189, s. 130–148.
- Dengler, K. L. – High, R. A. – Moga, D. C., et al.: Overactive bladder and cognitive impairment: The American Urogynecologic Society and Pelvic Floor Disorders Research Foundation State-of-the-Science Conference Summary Report. *Urogynecology*, 2023, 29, suppl. 1, s. S1–S19.
- Mostafaei, H. – Salehi-Pourmehr, H. – Jilch, S., et al.: Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: a systematic review and network meta-analysis. *Eur Urol Focus*, 2022, 8, s. 1072–1089.
- Chu, F. M. – Dmochowski, R.: Pathophysiology of overactive bladder. *Am J Med*, 2006, 119, suppl. 1, s. 3–8.
- Chapple, C. R. – Nazir, J. – Hakim, Z., et al.: Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. *Eur Urol*, 2017, 72, s. 389–399.
- Murray, B. – Miles-Thomas, J. – Park, A. J., et al.: Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective. *J Comp Eff Res*, 2019, 8, s. 61–71.
- DeLancey, J. O.: Structural support of the urethra as it relates to stress urinary incontinence: the hammock hypothesis. *Am J Obstet Gynecol*, 1994, 170, s. 1713–1720, diskuze s. 1720–1723.
- Ulmsten, U. – Henriksson, L. – Johnson, P., et al.: An ambulatory surgical procedure under local anesthesia for treatment of female urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*, 1996, 7, s. 81–85, diskuze s. 85–86.
- Kuuv, N. – Nilsson, C. G.: A nationwide analysis of complications associated with the tension-free vaginal tape (TVT) procedure. *Acta Obstet Gynecol Scand*, 2002, 81, s. 72–77.
- Delorme, E.: Transobturator urethral suspension: mini-invasive procedure in the treatment of stress urinary incontinence in women. *Prog Urol*, 2001, 11, s. 1306–1313.
- de Leval, J.: Novel surgical technique for the treatment of female stress urinary incontinence: transobturator vaginal tape inside-out. *Eur Urol*, 2003, 44, s. 724–730.
- Serdinsek, T. – Martan, A. – Svabik, K., et al.: Is the fixation of single incision TVT-S tape as good as that of transobturator tape? An ultrasound study of randomized trial results. *Int Urogynecol J*, 2021, 32, s. 141–148.
- Masata, J. – Svabik, K. – Zvara, K., et al.: Comparison of the efficacy of tension-free vaginal tape obturator (TVT-O) and single-incision tension-free vaginal tape (Ajust) in the treatment of female stress urinary incontinence: a 1-year follow-up randomized trial. *Int Urogynecol J*, 2016, 27, s. 1497–1505.
- Masata, J. – Svabik, K. – Zvara, K., et al.: Comparison of short term results of TVT-O and TVT-S in the surgical treatment of stress urinary incontinence | Porovnání krátkodobých výsledků TVT-O a TVT-S v operační léčbě stresové inkontinence moči. *Ceska Gynekol*, 2012, 77, s. 350–357.
- Krofta, L. – Feyereisl, J. – Velebil, P., et al.: TVT-S for surgical treatment of stress urinary incontinence: prospective trial, 1-year follow-up. *Int Urogynecol J*, 2010, 21, s. 779–785.
- Trabuco, E. C. – Carranza, D. – El Nashar, S. A., et al.: Reoperation for urinary incontinence after retropubic and transobturator sling procedures. *Obstet Gynecol*, 2019, 134, s. 333–342.
- Imamura, M. – Hudson, J. – Wallace, S. A., et al.: Surgical interventions for women with stress urinary incontinence: systematic review and network meta-analysis of randomised controlled trials. *BMJ*, 2019, 365, s. 11842.
- Shek, K. L. – Dietz, H. P.: Ultrasound imaging of slings and meshes in urogynecology. *Ultrasound Obstet Gynecol*, 2021, 57, s. 526–538.
- Dietz, H. P.: Ultrasound in the investigation of pelvic floor disorders. *Curr Opin Obstet Gynecol*, 2020, 32, s. 431–440.
- Kociszewski, J. – Kolben, S. – Barski, D., et al.: Complications following tension-free vaginal tapes: accurate diagnosis and complications management. *Biomed Res Int*, 2015, 2015, s. 538391.
- Burch, J. C.: Urethrovaginal fixation to Cooper's ligament for correction of stress incontinence, cystocele, and prolapse. *Am J Obstet Gynecol*, 1961, 81, s. 281–290.
- Goldman, H. B.: Joint position statement on midurethral slings for stress urinary incontinence. *NeuroUrol Urodyn*, 2022, 41, s. 31–34.
- Klarskov, N. – Lose, G.: Urethral injection therapy: what is the mechanism of action? *NeuroUrol Urodyn*, 2008, 27, s. 789–792.
- Krhut, J. – Martan, A. – Jurakova, M., et al.: Treatment of stress urinary incontinence using polyacrylamide hydrogel in women after radiotherapy: 1-year follow-up. *Int Urogynecol J*, 2016, 27, s. 301–305.

Význam antimüllerického hormonu pro klinickou praxi

MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, 3. LF UK, IPVZ, Praha

- Cate, R. L. – Mattaliano, R. J. – Hession, C., et al.: Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells. *Cell*, 1986, 45, s. 685–698.
- Price, J. M. – Donahoe, P. K. – Ito, Y., et al.: Programmed cell death in the Mullerian duct induced by Mullerian inhibiting substance. *Am J Anat*, 1977, 149, s. 353–1476.
- Jost, A.: Problems of fetal endocrinology: the gonadal and hypophyseal hormones. *Recent Prog Hormone Res*, 1953, 8, s. 379–413.
- Cate, R. L. – Mattaliano, R. J. – Hession, C., et al.: Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells. *Cell*, 1986, 45, s. 685–698.
- Rodgers, R. J. – Abbott, J. A. – Walters, K. A., et al.: Translational physiology of anti-Müllerian hormone: clinical applications in female fertility preservation and cancer treatment. *Front Endocrinol*, 2021, 12, s. 689532.
- Dewailly, D. – Andersen, C. Y. – Balen, A., et al.: The physiology and clinical utility of anti-Müllerian hormone in women. *Hum Reprod Update*, 2014, 20, s. 370.
- Moridi, I. – Chen, A. – Tal, O., et al.: The association between vitamin D and anti-Müllerian hormone: a systematic review and meta-analysis. *Nutrients*, 2020, 12, s. 1567.
- Hariton, E. – Shirazi, T. N. – Douglas, N. C., et al.: Anti-Müllerian hormone levels among contraceptive users: evidence from a cross-sectional cohort of 27,125 individuals. *Am J Obstet Gynecol*, 2021, 225, s. 515.e1–515.e10.
- Whitworth, K. W. – Baird, D. D. – Steiner, A. Z., et al.: Anti-Müllerian hormone and lifestyle, reproductive, and environmental factors among women in rural South Africa. *Epidemiology*, 2015, 26, s. 429–435.
- Nelson, S. M. – Klein, B. M. – Arce, J.-C.: Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials. *Fertility and Sterility*, 2015, 103, s. 923–30.e1.
- Broer, S. L. – Dölleman, M. – Opmeer, B. C., et al.: AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. *Hum Reprod Update*, 2011, 17, s. 46.
- Steiner, A. Z. – Pritchard, D. – Stanczyk, F. Z., et al.: Association between biomarkers of ovarian reserve and infertility among older women of reproductive age. *JAMA*, 2017, 318, s. 1367.
- Lutchman Singh, K. – Muttukrishna, S. – Stein, R. C., et al.: Predictors of ovarian reserve in young women with breast cancer. *Br J Cancer*, 2007, 96, s. 1808.
- ACOG Committee Opinion No. 773: The use of antimüllerian hormone in women not seeking fertility care. *Obstet Gynecol*, 2019, 133, s. e274.
- Almog, B. – Shehata, F. – Suissa, S., et al.: Age-related normograms of serum antimüllerian hormone levels in a population of infertile women: a multicenter study. *Fertil Steril*, 2011, 95, s. 2359.
- Weghofer, A. – Dietrich, W. – Barad, D. H., et al.: Live birth chances in women with extremely low-serum anti-Müllerian hormone levels. *Hum Reprod*, 2011, 26, s. 1905.
- Su, H. I. – Sammel, M. D. – Homer, M. V., et al.: Comparability of anti-Müllerian hormone levels among commercially available immunoassays. *Fertil Steril*, 2014, 101, s. 1766.
- Gnoth, C. – Schüring, A. N. – Friol, K., et al.: Relevance of anti-Müllerian hormone measurement in a routine IVF program. *Hum Reprod*, 2008, 23, s. 1359.
- Toner, J. P. – Seifer, D. B.: Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone. *Fertil Steril*, 2013, 99, s. 1825.
- Bedoschi, G. – Navarro, P. A. – Oktay, K.: Chemotherapy-induced damage to ovary: mechanisms and clinical impact. *Future Oncol*, 2016, 12, s. 2333–2344.
- Kalich-Philosoph, L. – Roness, H. – Carmely, A., et al.: Cyclophosphamide triggers follicle activation and burnout; AS101 prevents follicle loss and preserves fertility. *Science Translational Medicine*, 2013, 5, 185ra62.
- Roness, H. – Spector, I. – Leichtmann-Bardoogo, Y., et al.: Pharmacological administration of recombinant human AMH rescues ovarian reserve and preserves fertility in a mouse model of chemotherapy, without interfering with anti-tumoural effects. *J Assist Reprod Genet*, 2019, 36, s. 1793–1803.

Antikoagulační léčba žilních tromboembolických příhod

MUDr. Karolína Kočí Interní klinika 1. LF UK a ÚVN, Praha

- Souhrnné údaje o dodávkách léčivých přípravků do lékáren a jiných zdravotnických zařízení dle léčivé látky a cesty podání. SÚKL. Dostupné z: www.sukl.cz/rok-2022, vyhledáno 7. 3. 2023.
- Smpc Pradaxa. Dostupné z: www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_cs.pdf, vyhledáno 7. 3. 2023.
- Smpc Eliquis. Dostupné z: www.ema.europa.eu/documents/product-information/eliquis-epar-product-information_cs.pdf, vyhledáno 7. 3. 2023.
- Smpc Xarelto. Dostupné z: www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_cs.pdf, vyhledáno 7. 3. 2023.
- Smpc Lixiana. Dostupné z: www.ema.europa.eu/documents/product-information/lixiana-epar-product-information_cs.pdf, vyhledáno 7. 3. 2023.
- Konstantinides, S. V. – Meyer, G. – Becattini, C., et al.: 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). *Eur Heart J*, 2020, 41, s. 543–603. Originální verze je volně dostupná z: <https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-Pulmonary-Embolism-Diagnosis-and-Management-of>, vyhledáno 15. 3. 2023.
- Karetová, D. – Chochola, M., et al.: *Vaskulární medicína*. Maxdorf, Praha, 2018.
- Karetová, D. – Bultas, J.: *Farmakoterapie tromboembolických stavů*. Maxdorf, Praha, 2015.

Obinutuzumab a bendamustin dosáhly u pěti pacientů s Waldenströmovou makroglobulinémií hlubší léčebné odpovědi než předchozí linie léčby

prof. MUDr. Zdeněk Adam, CSc. | prof. MUDr. Luděk Pour, Ph.D. Interní hematologická a onkologická klinika LF MU a FN Brno

MUDr. Ing. David Zeman, Ph.D. Ústav laboratorní medicíny – Oddělení klinické biochemie, LF MU a FN Brno

doc. MUDr. Marta Krejčí, Ph.D. | MUDr. Viera Sandecká, Ph.D. Interní hematologická a onkologická klinika LF MU a FN Brno

- Wang, H. – Chen, Y. – Li, F., et al.: Temporal and geographic variations of Waldenström macroglobulinemia incidence: a large population-based study. *Cancer*, 2012, 118, s. 3793–3800.
- Adam, Z. – Pour, L. – Zeman, D., et al.: Waldenströmova makroglobulinémie – klinické projevy a přehled léčby včera, dnes a zítra. *Klin Onkol*, 2023, 36, s. 1–15.
- Kastritis, E. – Gavriatopoulou, M. – Kyrtonis, M. C., et al.: Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. *Blood*, 2015, 126, s. 1392–1394.
- Kašćák, M. – Hájek, R. – Minařík, J., et al.: Diagnostika a léčba Waldenströmovy makroglobulinémie. *Transfuze Hematol Dnes*, 2022, 28, suppl. 1, s. S44–S74.
- Mössner, E. – Brünker, P. – Moser, P., et al.: Increasing the efficacy of CD20 antibody therapy through the engineering of a new Type II anti-CD20 antibody with enhanced direct and immune effector cell mediated B cell cytotoxicity. *Blood*, 2010, 115, s. 4393–4402.
- Leblond, V. – Kastritis, E. – Advani, R., et al.: Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. *Blood*, 2016, 128, s. 1321–1328.
- Gavriatopoulou, M. – Kastritis, E. – Kyrtonis, M. C., et al.: Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. *Leuk Lymphoma*, 2017, 58, s. 1506–1508.
- Furman, R. R. – Eradat, H. A. – DiRienzo, C. G., et al.: Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinemia: an open-label, single-arm, phase 2 study. *Lancet Haematol*, 2017, 4, s. e24–e34.
- Buske, C.: Ofatumumab: another way to target CD20 in Waldenström's macroglobulinemia? *Lancet Haematol*, 2017, 4, s. e4–e5.
- Sehn, L. H. – Chua, N. – Mayer, J., et al.: Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. *Lancet Oncol*, 2016, 17, s. 1081–1093.
- García-Muñoz, R. – López-Díaz-de-Cerio, A. – Feliu, J., et al.: Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity. *Immunol Res*, 2016, 64, s. 548–557.
- Herter, S. – Herting, F. – Mundigl, O., et al.: Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. *Mol Cancer Ther*, 2013, 12, s. 2031–2042.
- Sehn, L. H. – Goy, A. – Offner, F. C., et al.: Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B cell non-Hodgkin lymphoma: final analysis of the GAUSS study. *J Clin Oncol*, 2015, 33, s. 3467–3474.
- Marcus, R. E. – Davies, A. J. – Ando, K., et al.: Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomized phase 3 GALLIUM study. *Blood*, 2016, 128, s. 6.
- Hidemann, W. – Barbui, A. M. – Canales, M. A., et al.: Immunotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. *J Clin Oncol*, 2018, 36, s. 2395–2404.
- Seymour, J. F. – Marcus, R. – Davies, A., et al.: Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. *Haematologica*, 2019, 104, s. 1202–1208.
- Jamois, C. – Gibiansky, E. – Gibiansky, L., et al.: Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy. *Br J Clin Pharmacol*, 2019, 85, s. 1495–1506.
- Salles, G. A. – Morschhauser, F. – Solal-Céligny, P., et al.: Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the Phase II GAUGUIN study. *J Clin Oncol*, 2013, 31, s. 2920–2926.
- Cheson, B. D. – Chua, N. – Mayer, J., et al.: Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. *J Clin Oncol*, 2018, 36, s. 2259–2266.
- Cheson, B. D. – Trask, P. C. – Gribben, J. G., et al.: Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. *Ann Hematol*, 2017, 96, s. 253–259.
- Marcus, R. – Davies, A. – Ando, K., et al.: Obinutuzumab for the

- first-line treatment of follicular lymphoma. *N Eng J Med*, 2017, 377, s. 1331–1344.
- 22 **Goede, V. – Fischer, K. – Engelke, A., et al.**: Obinutuzumab as front-line treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. *Leukemia*, 2015, 29, s. 1602–1604.
- 23 **Vitolo, U. – Trněný, M. – Belada, D., et al.**: Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final results from an open-label, randomized phase 3 study (GOYA). *Blood*, 2016, 128, s. 470–470.
- 24 **Sehn, L. H. – Martelli, M. – Trněný, M., et al.**: A randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final analysis of GOYA. *J Hematol Oncol*, 2020, 13, s. 71.
- 25 **Casasnovas, R.-O. – Salles, G. A. – Oberic, L., et al.**: Obinutuzumab versus rituximab in combination with ACVBP-14 or CHOP-14 following a PET-driven strategy in Aa-IPI 1–3 DLBCL patients (< 60 years): third planned interim and final analyses of the gained trial. *Blood*, 2017, 130, s. 190–190.
- 26 **Herold, M. – Hoster, E. – Janssens, A., et al.**: Immunochemotherapy and maintenance with obinutuzumab or rituximab in patients with previously untreated marginal zone lymphoma in the randomized GALLIUM trial. *Hemasphere*, 2022, 6, s. e699.
- 27 **Luo, C. – Wu, G. – Huang, X. – Ma, Y., et al.**: Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20⁺ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis. *Sci Rep*, 2021, 11, s. 3255.
- 28 **Amhaz, G. – Bazarbachi, A. – El-Cheikh, J.**: Immunotherapy in indolent non-Hodgkin's lymphoma. *Leuk Res Rep*, 2022, 17, s. 100325.
- 29 **Guzauskas, G. F. – Masaquel, A. – Thuresson, P. O., et al.**: Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States. *Leuk Lymphoma*, 2019, 60, s. 1668–1676.
- 30 **Tomowiak, C. – Poulain, S. – Herbaux, C., et al.**: Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. *Blood Adv*, 2021, 5, s. 2438–2446.
- 31 **Adam, Z. – Krejčí, M. – Pour, L., et al.**: Obinutuzumab v léčbě pacientky s Waldenströmovou makroglobulinémií netolerující rituximab – popis případu. *Transfuze Hematol Dnes*, 2021, 27, s. 160–165.
- 32 **Freeman, C. L. – Sehn, L. H.**: A tale of two antibodies: obinutuzumab versus rituximab. *Br J Haematol*, 2018, 182, s. 29–45.